已收盤 09-19 16:00:00 美东时间
-0.001
-0.14%
Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, will present updated data from the ongoing global Phase 1/2
09-16 19:05
Passage Bio Q2 Income From Operations USD -17.378 Million
08-08 19:00
Passage Bio (NASDAQ:PASG) traded higher on Thursday after the company announced a series of agreements with GEMMA Biotherapeutics, including a deal to out-license its programs targeting pediatric lyso...
08-02 02:03
Passage Bio: Post Gemma Sublicenses, to Get up to Additional $10 Mln Contingent...
08-01 19:12
Passage Bio: Post Gemma Sublicenses, to Get up to Additional $114 Mln in Develo...
08-01 19:12
Passage Bio Inc: On July 31, Entered Series of Sublicense Agreements With Gemma
08-01 19:11
Passage Bio: Post Gemma Sublicenses, to Get Initial Payments of $10 Mln for Pur...
08-01 19:11
Passage Bio Inc - to Initiate Dosing of Ftd-C9Orf72 Patients in 1H 2025
07-16 19:01
Passage Bio Announces Positive Feedback From FDA on Expansion of Uplift-D Trial...
07-16 19:00
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
07-08 07:01